Significance of brain natriuretic peptide among patients with cardiac dysfunction and in pregnancy by Babencu, E.
Nr. 4 (322), 2011
52
R E V I EW  A R T I C L E S
Significance of Brain Natriuretic Peptide among Patients  
with Cardiac Dysfunction and in Pregnancy
E. Babencu
Laboratory of Obstetrics and Gynecology, Scientific Research Institute of Mother and Child Health Care
93, Burebista Street, Chisinau, Republic of Moldova
Corresponding author: + 37379570591.  E-mail: e.babencu@yahoo.com
Manuscript received March 18, 2011; revised June 01, 2011
Abstract
The cardiac natriuretic peptides or the natriuretic hormones produced and secreted by human cardiomyocyte, form a family of bioactive peptides. 
Different types of natriuretic peptides have been identified, the most important being atrial natriuretic peptide (ANP) and brain natriuretic peptide the 
(BNP).  These are derived from the N-terminal portion of proANP (NT-proANP) and proBNP (NT-proBNP) chains.  The study of natriuretic peptide, and 
other neurohormonal regulators of the cardiovascular system marked the emergence of a new field of integrated basic and clinical research - cardiovascular 
endocrinology.  The most commonly used in clinical practice are the natriuretic peptide BNP and NT-proBNP.  Although the precursor is synthesized 
and released in both the atria and the ventricles, the main source of release is the left ventricle.  BNP/NT-proBNP is secreted in response to the increased 
tension on the heart wall, as occurs in the case of volume overload of any etiology, and secretion is directly proportional to the degree of wall stress.  As 
a result, scholars have suggested that determination of the cardiac peptides may be clinically relevant for making an early and rapid diagnosis of heart 
failure, evaluating the severity of cardiac insufficiency and wall stress, as well as for monitoring the efficacy of therapeutic measures
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Значение мозгового натрийуретического пептида у пациентов  
с нарушением функции сердца и у беременных
Сердечный натрийуретический пептид или сердечные натрийуретические гормоны, производимые и выделяемые кардиомиоцитами, 
образуют семейство биологически активных пептидов.  До сих пор было определено несколько видов натрийуретических пептидов, наиболее 
важными из которых являются: предсердный натрийуретический пептид (ПНП), мозговой натрийуретический пептид (МНП), производные 
от терминальной части цепи проПНП N-(NT-proANP) и проМНП (NT-проBNP).  Исследование натрийуретических пептидов и других 
нейрогормональных систем, участвующих в нейроэндокринной регуляции функции сердечнососудистой системы, привело к появлению нового 
комплексного поля фундаментальных и клинических исследований – сердечнососудистой эндокринологии.  Наиболее распространенные - 
натрийуретический пептид МНП и его предшественник NT-проМНП, которые синтезируются и секретируются как в предсердиях, так и в 
желудочках.  МНП/NT-проМНП выделяется в ответ на рост давления на сердечную стенку при повышении объема перегрузки любого генеза, 
при этом секреция прямо пропорциональна степени напряжения миокарда.  Чаще всего, объем перегрузки вызван сердечной недостаточностью 
при пороках сердца.  Исходя из вышесказанного, некоторые ученые полагают, что определение сердечного пептида важно в качестве средства 
ранней и быстрой диагностики сердечной недостаточности, а также для оценки эффективности лечебных мероприятий.
Ключевые слова: пороки сердца, натрийуретические пептиды, беременности осложнения.
Introduction
Despite advances in the treatment of heart failure, there 
are still problems in correctly identifying, diagnosing, and 
stratifying patients with this condition.  To initiate optimal 
and timely treatment it is necessary to identify heart failure 
early in its course, however diagnosis is often difficult because 
of nonspecific symptoms and the frequent presence of heart 
failure in other diseases.  Determination of cardiac peptides 
is at present a straightforward and rapid diagnosis of heart fa-
ilure, and is also useful for assessing its severity and prognosis 
as well as the effectiveness of therapeutic measures [1, 20].
Types and mechanisms of action of natriuretic peptides
Cardiac natriuretic peptide or natriuretic hormones pro-
duced and secreted by human cardiomyocytes, are a family of 
bioactive peptides.  So far the focus has been on identifying 
the types of natriuretic peptides, the most important being: 
atrial natriuretic peptide (ANP), brain natriuretic peptide 
(BNP), other peptides derived from N-terminal portion of 
proANP chains (NT-proANP) and proBNP (NT-proBNP) 
and C-type natriuretic peptide (CNP), which is produced 
and secreted by cardiomyocytes and other tissues as well. 
The discovery of new forms of the natriuretic peptide family 
actively continues [16].
Identification of the natriuretic peptides, and other neu-
rohormonal systems involved in regulating the cardiovascular 
neuroendocrine, marked the emergence of a new field of 
integrated fundamental and clinical research - cardiovascular 
endocrinology [16].
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The most commonly used in clinical practice are the na-
triuretic peptides BNP and NT-proBNP precursor.  They are 
synthesized and released in both the atria and the ventricle, 
however most of the secretion is mainly from the left ventricle. 
BNP/NT-proBNP is secreted in response to increased tension 
on the cardiac walls, as occurs in cases of volume overload of 
various etioloies, and secretion is directly proportional to the 
degree of the wall tension.
BNP/NT-proBNP is a natural antagonist of the renin-
angiotensin-aldosterone system, acting on the balance of 
sodium and water, having effects on decreasing peripheral 
vascular resistance, relaxing vascular smooth muscle, and 
inducing decrease in blood pressure, natriuresis and diuresis. 
These effects are achieved by binding to natriuretic peptide 
receptors on cell surfaces.  These receptors are widespread in 
the cardiovascular system, lungs, kidneys, skin and central 
nervous system.
Diagnostic capacity
Natriuretic peptides are biomarkers and important means 
of diagnosis.  Currently, plasma levels of natriuretic peptides 
or their precursors, especially BNP and NT-proBNP are useful 
in diagnosing heart failure and are included in all guidelines 
for heart failure [1].
The increased level of natriuretic peptides may indicate left 
ventricular diastolic dysfunction, left ventricular hypertrophy, 
valvular, acute or chronic cardiac ischemia, hypertension and 
pulmonary embolism.
The best predictive value of BNP/NT-proBNP was obtai-
ned for detection of severe left ventricular systolic dysfunction 
with concomitant ventricular hypertrophy: sensitivity 71% 
and specificity of 86%.  Thus the use of BNP/NT-proBNP 
for the exclusion of the diagnosis of heart failure is based on 
very high negative predictive value [1].  Negative predictive 
value of BNP/NT-proBNP in suspected left ventricular systolic 
dysfunction with concomitant ventricular hypertrophy was 
99%, sensitivity of 71%.  Thus, BNP/NT-proBNP is able to 
detect most subjects with severe left ventricular dysfunction 
and concomitant ventricular hypertrophy with minimal risk 
of missing the diagnosis of heart failure.
The diagnostic utility of BNP/NT-proBNP in detecting 
systolic dysfunction, diastolic dysfunction or left ventricular 
hypertrophy has recently been confirmed in a clinical study 
of 94 patients, in addition, a population study suggested that 
measurement of BNP/NT-proBNP are effective method for 
screening patients with left ventricular dysfunction.
Left ventricular systolic function is preserved in 20-50% 
of patients with heart failure.  Although these patients have a 
lower mortality compared with patients with left ventricular 
systolic dysfunction, morbidity is similar.  In patients with 
preserved left ventricular systolic function there is limited 
information on severity and prognostic factors.  Determina-
tion of NT-proBNP is a strong test for the diagnosis of heart 
failure regardless of left ventricular systolic function.
S. Wright has shown that NT-proBNP is present in high 
levels in cardiac dysfunction and may improve the diagnostic 
accuracy of heart failure.  Atisha Tschope D. and C. [20] have 
found a good diagnostic accuracy of BNP and NT-proBNP 
for heart failure, especially in cases of systolic dysfunction as 
compared with diastolic dysfunction [5, 20].  However, BNP/
NT-proBNP allows excellent diagnostic accuracy of isolated 
diastolic heart failure as well.  NT-proBNP can reliably detect 
isolated diastolic dysfunction in symptomatic patients and 
is a useful tool to identify patients with reduced exercise 
tolerance of non-cardiac origin [20].  NT-proBNP may be 
recommended as a test to exclude patients with heart failure. 
Moreover, in patients with increased risk of heart failure due 
to coronary disease, presence of Q waves on ECG or left bun-
dle-branch block major, even if asymptomatic, screening by 
NT-proBNP may provide relevant diagnostic and prognostic 
information [1].
In general, the predictive values of BNP/NT-proBNP vary 
depending on the degree of left ventricular dysfunction, in-
creasing with severity of heart damage and modulated by the 
presence or absence of ventricular hypertrophy.
Elevated levels of ANP, BNP and NT-proANP were found 
in patients with cardiac dysfunction of different etiologies 
(tachycardia, valvular stenosis, or ventricular dysfunction). 
High circulating levels of natriuretic peptides are associated 
with: 1) elevated atrial and pulmonary pressures; 2) reduction 
of systolic and diastolic ventricular function; 3) left ventricular 
hypertrophy and 4) severe myocardial infarction.  Although 
both peptides, ANP and BNP, are elevated in serum in the 
presence of left ventricular hypertrophy, BNP is a better in-
dicator for left ventricular hypertrophy.
Major value of plasma natriuretic peptides in exami-
ning patients with suspected cardiac disease is based on the 
following assumptions: 1) a normal value is not consistent 
with cardiac disease; 2) significantly higher levels may be 
an indication for further assessment of the causes of cardiac 
dysfunction and 3) significant increase in plasma levels of 
natriuretic peptides after myocardial infarction can identify 
patients at high risk of death.
Echocardiography is the “gold standard” test for examining 
patients with suspected left ventricular failure, but cost and 
availability limit its use for routine screening.
Natriuretic peptides, especially BNP and NT-proB-
NP, are good markers for the screening of heart failure in 
symptomatic patients.  NT-proBNP has a high sensitivity, 
excellent prognostic impact, high stability.  It is easy to use 
and is cost-effective.  Natriuretic peptides may be used as 
pre-echocardiography screening test: to assess the need for 
echocardiography.  If NT-proBNP is negative, heart failure 
is unlikely and further evaluation of this diagnosis may not 
be necessary.  If elevated levels are detected, it is necessary 
to evaluate the cardiovascular system with further testing, 
including echocardiography [1].
It has been shown that BNP/NT-proBNP can identify a low 
left ventricular ejection fraction amongst a general population 
of hospitalized patients [8] as well as amongst patients with 
coronary heart disease [7].  In particular, the determination 
of BNP/NT-proBNP may be useful for differentiating healthy 
subjects from patients with different stages of heart failure.
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Thus, in contemporary clinical practice, BNP and NT-
proBNP determination is usually a test to exclude subclinical 
cardiac disease that has increased wall tension as an under-
lying factor.  This is important both for primary care and 
specialized medical care.  The most widely accepted is the use 
of natriuretic peptides for heart failure screening to identify 
patients for further cardiac testing (echocardiography and 
other investigations evaluating expensive) and pharmacolo-
gical treatment.
Prognostic value
The BNP/NT-proBNP may be useful for determining the 
prognosis of long-term survival in patients with heart failure 
and/or after myocardial infarction.
Studies have shown that in patients with decompensated 
heart failure, regardless of left ventricular systolic function 
status, NT-proBNP identifying the risk of complications [5].
The level of BNP/NT-proBNP is a strong and independent 
predictor of cardiovascular mortality and sudden death in 
patients with myocardial infarction, chronic heart failure, and 
acute coronary syndromes [2] as well as in elderly without any 
known cardiovascular disorders.
In randomized study looking at patients with ejection 
fraction below 25% and symptoms of chronic congestive heart 
failure at rest or with minimal effort, NT-proBNP proved to 
be a strong predictor for subsequent all-cause mortality or 
hospitalization for heart failure.
Even a single measurement of BNP/NT-proBNP, obtained 
in the first days after onset of ischemic symptoms, provides 
sufficient information for use in risk stratification of patients 
with acute coronary syndromes.  BNP is also a useful marker 
for monitoring severity of right sided heart failure in pulmo-
nary hypertension [4].
Multiple studies suggest that BNP has a better clinical 
utility than other cardiac natriuretic hormones.  Plasma BNP 
is more useful than plasma ANP to assess mortality in patients 
with chronic congestive heart failure, as plasma levels of BNP 
provide prognostic information independent of hemodynamic 
parameters.
An increased preoperative plasma BNP level is a strong 
and independent predictor of postoperative atrial fibrillation, 
in which case prophylactic antiarrhythmic therapy should be 
considered.
To define the value suggestive of heart failure, many stu-
dies [13, 19] use the level of BNP > 100 pg/ml. In all cases of 
elevated BNP, serum creatinine should be checked to exclude 
renal dysfunction [19].
Studies that have assessed the value of NT-proBNP, obtai-
ned values of “rule out” between 100-160 ng/ml which have 
provided a negative predictive value of 92-100% and a positive 
predictive value between 15 and 76%, a sensitivity of 94-98% 
and a specificity of 35-68% [10].  Currently, there is general 
agreement for the cutoff value of 125 ng/1 in patients with 
symptoms suggestive of heart failure [1].
Some studies indicate an increase in natriuretic peptide 
concentration with age and the female sex hormones in 
healthy adults, this increase is probably caused by changes in 
natriuretic peptide metabolism, as well as age-related changes 
in cardiac and renal functions [8] and should be taken into 
account in the calculation of reference values for cardiac 
natriuretic peptide.
So far, there is no consensus on the best methods of quan-
titative evaluation of cardiac natriuretic peptides.  To facilitate 
widespread clinical applicability of the determination of these 
hormones, further research is necessary in order to select the 
most reliable, sensitive, specific and rapid tests.
Therefore, natriuretic peptides are currently considered 
the most promising markers of cardiac function and cardi-
ovascular prognosis.  BNP and NT-proBNP measurement 
was introduced in clinical practice for diagnosis and risk 
stratification of CVD, especially in heart failure [1].  Althou-
gh natriuretic peptides may predict a beneficial treatment in 
ischemic left ventricular dysfunction, assessing their role in 
monitoring the treatment remains to be determined.
Natriuretic peptide in pregnant women with CVD
Although clinical and echocardiographic predictors of 
cardiac complications during pregnancy have been identified 
[14], current risk stratification does not include adequate 
assessment of cardiac adaptation of the mother during 
pregnancy.  In addition, because the symptoms of cardiac 
decompnesation can mimic other pregnancy symptoms, 
clinical diagnosis of cardiac dysfunction is more difficult in 
pregnant women.  Therefore, there is an important role for 
the detection of cardiac decompensation using biochemical 
markers such as serum natriuretic peptides [19].
Serum concentrations of NT-proBNP can be used to 
monitor heart function during pregnancy, and normal values 
have been suggested for this purpose [9].
In nonpregnant patients with cardiac disease (congenital 
or acquired), higher BNP levels at rest are correlated with 
latent ventricular failure, as evidenced during exercise [12]. 
In spite of hemodynamic changes in pregnancy, most healthy 
pregnant women during pregnancy and after birth have ele-
vated levels of BNP that remain stable compared with healthy 
nonpregnant women [13].  On the other hand, preeclampsia 
and gestational hypertension are associated with progressively 
increasing levels of NT- proBNP [9].
NT-proBNP, evaluated and compared with dynamic 
echocardiographic data, is a better tool for clinical monito-
ring and management of pregnant women with pre-existing 
dilated cardiomyopathy [3], severe congenital aortic stenosis, 
hypertension and preeclampsia [15, 18].  NT-proBNP levels 
increase in pregnant women with hypertensive disorders, 
compared with pregnant women with normal blood pressure 
level (81 pg/ml and 37 pg/ml, respectively, p < 0.001) [15], and 
this increase is progressive.  Depending on the severity of the 
disease, proBNP levels can reach different peaks: gestational 
hypertension (64 pg/ml), mild preeclampsia (89 pg/ml) and 
severe preeclampsia (157 pg/ml) [15].  Moreover, the elevated 
value of NT-proBNP early in the pregnancy course can help 
predict the occurrence of future complications [3].
Results of the first prospective study to examine the BNP 
levels in pregnant women with cardiac dysfunction were 
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published in 2010.  The study had two objectives (estimating 
BNP levels in pregnant women with cardiac dysfunction, and 
assessing the relationship between BNP levels and cardiac 
complications of pregnant women) and found higher mean 
values of BNP levels in women with cardiac dysfunction com-
pared with healthy women.  All women with complications 
during pregnancy had a higher BNP level of 100 pg/ml [19].
There is a subgroup of pregnant women with cardiac 
disease who have high BNP levels during pregnancy, but no 
clinical cardiac complications.  But the significance of this 
finding requires further study [13].
In women with a risk score (low risk for cardiac compli-
cations), the rate of maternal cardiac complications during 
pregnancy was 0% in women with BNP levels < 100 pg/ml 
and 8% in women with BNP levels > 100 pg/ml.  Women with 
a score of l (intermediate risk for cardiac complications), the 
rate of maternal cardiac complications during pregnancy was 
0% in women with BNP levels < 100 pg/ml and 60% in women 
with BNP levels > 100 pg/ml (p < 0.03) [19].
There is some evidence that suggests that pregnancy 
adversely affects the natural course of cardiac function in 
women with left ventricular systolic dysfunction [12] and 
could have delayed effects on ventricular function in the fu-
ture [20].  Therefore, this group of women, especially those 
with an abnormally high BNP level during pregnancy should 
continue surveillance after pregnancy.
Thus, normal BNP levels during pregnancy in women with 
CVD predict a low risk for maternal cardiac complications. 
No women with BNP levels < 100 pg/ml showed any cardiac 
complications, with a negative predictive value of 100% for 
identification of cardiac complications during pregnancy [19].
Heart failure is a particular risk in pregnant women with 
acquired valvular heart disease.  For a sensitive diagnosis, an 
early and less costly screening method may be proposed - the 
determination of terminal fragment BNP or NT-proBNP 
levels, which increases proportionally with the degree of 
heart failure.
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